What did @kianajardot actually say?
On her third dose of Melanotan 2, @kianajardot reported that diluting the peptide more than she originally had made her side effects "minimized" and "bearable." She specifically called out flushing and mild nausea as persistent but tolerable, compared to a previous experience that made her feel like she was "dying." She framed this as an update, not a recommendation, which is worth noting.
The implicit claim here is that adjusting reconstitution volume, essentially lowering the concentration per drawn dose, reduced the intensity of her adverse effects. That's a mechanistically reasonable thing to say. Whether it's actually the concentration change or simply her body adapting to the compound on repeated exposure is a different question entirely, and one she doesn't address.
Does the science back this up?
Partially, yes. Melanotan 2 is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), and its side effect profile, including flushing, nausea, and spontaneous erections in male users, is well-documented in the literature. Lower effective doses do appear to reduce side effect severity.
A clinical study by Dorr et al. (1996, Journal of Clinical Oncology) on the parent compound Melanotan 1 found dose-dependent nausea and flushing responses. Research by Hadley (2005, Peptides) on Melanotan 2 specifically documented that flushing and gastrointestinal symptoms were among the most common adverse events at standard doses. The dose-response relationship for these side effects is real. If she drew the same volume of liquid but it was more dilute, she effectively administered a lower dose, and a lower dose producing fewer side effects is consistent with what the studies show.
What the science does not support is the idea that dilution alone is a safe or reliable titration strategy without knowing exactly what you're working with.
What did they get wrong (or right)?
She gets partial credit for the intuition. Reducing the effective dose by increasing reconstitution volume is a real harm-reduction approach, and the fact that she noticed reduced symptoms on what amounts to a lower dose is consistent with pharmacological reality. That's not nothing.
What's missing is important, though. She doesn't address whether the improvement is from lower dosing, physiological tolerance building across three exposures, or some combination. Repeated exposure to Melanotan 2 does appear to produce tachyphylaxis-like effects for some side effects, meaning the body adapts. A paper by King et al. (2007, Journal of Sexual Medicine) noted that some adverse effects diminished with continued use in study participants.
She also doesn't flag that Melanotan 2 is not approved by the FDA, is not a regulated pharmaceutical product, and that unverified peptides sourced outside clinical settings carry real contamination and dosing accuracy risks. Framing this as a straightforward "update" without that context is incomplete at best.
What should you actually know?
Melanotan 2 sits in a genuinely complicated space. It has legitimate research history, it activates melanocortin receptors and does produce tanning and other effects, but it has never completed Phase 3 clinical trials and is not an approved drug anywhere. The version being discussed here is almost certainly a research-grade or gray-market compound, which means purity, sterility, and actual peptide content are unknowns.
The side effects she describes, flushing and nausea, are among the milder documented reactions. More serious concerns in the literature include uncontrolled pigmentation changes, potential effects on existing nevi (moles), and cardiovascular effects at higher doses. Langan et al. (2021, JAMA Dermatology) raised concerns about melanocortin agonists and melanoma risk, though causation has not been established.
If you're considering any peptide with this kind of side effect profile, that conversation belongs with a licensed clinician, not a TikTok comment section.
Bottom line on this video
This is an honest personal update, not a sales pitch or false medical claim. The core observation, that more dilute dosing reduced her side effects - is pharmacologically consistent with available evidence. But it's personal anecdote without controls, and it omits the significant regulatory and safety context around Melanotan 2 that anyone watching this video deserves to hear.
- She did not claim it cures anything, which keeps her out of the most dangerous misinformation territory.
- She did not prescribe a dose or tell viewers to do what she did.
- What she did leave out is the part about this being an unregulated, unapproved compound with a real adverse event profile that extends beyond what she experienced.